AI could reduce pharma R&D costs by 30% to 40% and shorten timelines by one to four years. The partnership expands Lilly’s existing AI supercomputer project with Nvidia’s DGX technology. Are you ahead ...

Eli Lilly and Nvidia are putting up to $1 billion on the table to see whether generative AI can compress the decade-long slog of drug development into something closer to a software cycle. The two ...

One of the major promises of artificial intelligence (AI) is its role in speeding up drug discovery. AI can process massive amounts of data far faster than humans, identifying potential drug ...

Eli Lilly (LLY) and Nvidia (NVDA) will invest up to $1B over five years in an AI drug discovery lab. AI could reduce pharma R&D costs by 30% to 40% and shorten timelines by one to four years. The ...